Anthropic AI for Science event livestreams today as the company pitches Claude to pharma and biotech leaders. The session ...

Over the past several years, we have seen accelerating technological change. Machine learning is accelerating drug discovery, ...

Adds potential first-in-class,N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads Strengthens the Novartis ...

Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...

In a second M&A announcement today, Zymeworks has reached an agreement to buy Theravance Biopharma, claiming rights to ...

Many new gene therapy treatments aren’t as profitable as predicted. But the reasons why don’t quite fit Goldman Sachs’ warning ...

Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy; Immuron is seeking a partner to support clinical development through regulatory approval and ...

Ligand Pharma (LGND) stock jumped in the final week of June, but the proximate cause was the pricing of $625M of convertible ...

Oversubscribed $225 million concurrent private investment in public equity ("PIPE") with available cash to the combined ...

By 2050, scientists estimate that antibiotic-resistant infections will be associated with more than eight million deaths ...

At an event for pharmaceutical executives, biotech founders, and researchers on Tuesday, Anthropic announced Claude Science, ...

USA News Group, There is a growing consensus in artificial intelligence that the models themselves are becoming interchangeable, and that ...